ATM and neuroblastoma: The ATM inhibitor AZD0156 has shown selective toxicity in melanoma cells, neuroblastoma, and preclinical models of colorectal cancer (Davis et al., 2022; Qin et al., 2022; Wong et al., 2022; Yilmaz et al., 2023).